var data={"title":"Icodextrin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Icodextrin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6353?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=icodextrin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Icodextrin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7869323\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Unrecognized hypoglycemia resulting from drug-device interaction (Extraneal): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only use glucose-specific monitors and test strips to measure blood glucose levels in patients using Extraneal (icodextrin) Peritoneal Dialysis Solution. Blood glucose monitoring devices using glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase (GDO)-based methods must not be used. In addition, some blood glucose monitoring systems using glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD)-based methods must not be used. Use of GDH-PQQ, GDO, and GDH-FAD-based glucose monitors and test strips has resulted in falsely elevated glucose readings (due to the presence of maltose). Falsely elevated glucose readings have led patients or health care providers to withhold treatment of hypoglycemia or to administer insulin inappropriately. Both of these situations have resulted in unrecognized hypoglycemia, which has led to loss of consciousness, coma, permanent neurological damage, and death. Plasma levels of Extraneal (icodextrin) and its metabolites return to baseline within approximately 14 days following cessation of Extraneal (icodextrin) administration. Therefore falsely elevated glucose levels may be measured up to two weeks following cessation of Extraneal (icodextrin) therapy when GDH-PQQ, GDO, and GDH-FAD-based blood glucose monitors and test strips are used.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">To avoid improper insulin administration, educate patients to alert health care providers of this interaction whenever they are admitted to the hospital.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer(s) of the monitor and test strips should be contacted to determine if icodextrin or maltose causes interference or falsely elevated glucose readings. For a list of toll free numbers for glucose monitor and test strip manufacturers, please contact the Baxter Renal Clinical Help Line (1-888-736-2543) or visit http://www.glucosesafety.com.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of unrecognized hypoglycemia that could result from a drug-device interaction, Extraneal is available only through a restricted program. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181621\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adept;</li>\n      <li>Extraneal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49308227\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Extraneal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181636\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Adhesiolytic;</li>\n      <li>\n        Dialysis Solution;</li>\n      <li>\n        Peritoneal Dialysate, Osmotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181622\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CAPD or APD (Extraneal):</b> Intraperitoneal: Given as a single daily exchange in CAPD or APD; dwell time of 8 to 16 hours is suggested</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Laparoscopic gynecologic surgery (Adept):</b> Intraperitoneal: Irrigate with at least 100 mL every 30 minutes during surgery; aspirate remaining fluid after surgery is completed, then instill 1 L into the cavity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181623\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181602\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intraperitoneal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adept: 4% (1000 mL, 1500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extraneal: 7.5% (2000 mL, 2500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181590\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8104265\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135933.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQCpqUktR+rsyRpdO1DCb6ig==&amp;TOPIC_ID=8769\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135933.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181604\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Intraperitoneal administration only; not for IV injection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adept: Warm to body temperature prior to use</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osmolarity: 278 mOsm/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extraneal: If using manual method, infuse into intraperitoneal cavity over 10 to 20 minutes. For increased comfort, may warm, using dry heat (eg, heating pad, warming plate), to 37&deg;C (98.6&deg;F) prior to administration; do not heat above 40&deg;C (104&deg;F). Do <b>not</b> immerse in water for warming or use a microwave oven to warm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Osmolarity: 282 to 286 mOsm/L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">pH: 5.0 to 6.0.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181603\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adept: Adjunct to surgery for the reduction of postsurgical adhesions in gynecologic laparoscopic adhesiolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extraneal: Daily exchange for the long dwell (8- to 16-hour) during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of end-stage renal disease (ESRD); improvement of long-dwell ultrafiltration and clearance of creatinine and urea nitrogen (compared to 4.25% dextrose) in patients with high average or greater transport characteristics as measured by peritoneal equilibration test (PET)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4432013\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>Special care is warranted in patients with diabetes:</b> Due to potential interference by maltose, careful attention must be given to glucose monitoring; only glucose monitors and test strips which employ the glucose-specific method should be used. Inaccurate methods (glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ], glucose-dye-oxidoreductase [GDO], and some glucose dehydrogenase flavin-adenine dinucleotide (GDH-FAD)-based methods)  can result in falsely elevated readings. Inaccurate readings may mask recognition of true hypoglycemia, or may prompt the administration of insulin, potentially leading to life-threatening consequences.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181594\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CAPD or APD (Extraneal&reg;):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (13%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory infection (15%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Peritonitis (26% vs 25% in controls) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">5% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (up to 6%), chest pain (5%), hypervolemia, hypotension </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (9%), dizziness </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatological: Rash (10%), pruritus, skin disorder </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia (5%), hyperphosphatemia, hypokalemia, hypoproteinemia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (8%), nausea (7%), dyspepsia (5%), diarrhea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic: Anemia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, pain, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough increased (7%), dyspnea </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Accidental injury (6%), flu syndrome (7%), infection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;5%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Orthostatic hypotension, CHF </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Confusion </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Exfoliative dermatitis, erythema multiforme, eczema, maculopapular rash, vesicobullous rash </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypercalcemia, hypochloremia, hypoglycemia, hyponatremia, alkaline phosphatase increased </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal enlargement, cramps </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: ALT increased, AST increased </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Infusion pain </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Cloudy effluent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Laparoscopic surgery (Adept&reg;):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Dysmenorrhea (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (6% to 17%), constipation (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Pyrexia (6%), insomnia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Flatulence (8%), abdominal pain (7%), abdominal distention (6%), vomiting (6%), diarrhea (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Dysuria (7%), urinary tract infection (7%); labial, vulvar, or vaginal swelling (6%); vaginal bleeding (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (9%), back pain (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (7%), cough (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Sterile peritonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181607\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to icodextrin, cornstarch, or any component of the formulation; glycogen storage disease; maltose or isomaltose intolerance; severe lactic acidosis (Extraneal only); infection (eg, peritonitis) of the abdominopelvic cavity, procedures with laparotomy incision, bowel resection or repair, appendectomy (Adept only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling (Extraneal):</i> Additional contraindications (not in US labeling): Acute renal failure, uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection, documented loss of peritoneal function or extensive adhesions that compromise peritoneal function, history of abdominal surgery in the month prior to beginning therapy, abdominal fistulae, tumors, open wounds, herniae or other conditions which compromise the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181592\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\tHypersensitivity reactions: Serious reactions, including anaphylaxis, toxic epidermal necrolysis, angioedema, serum sickness, erythema multiforme, and vasculitis have been reported. Discontinue infusion immediately and drain solution from the peritoneal cavity if signs or symptoms of a suspected hypersensitivity reaction develop. Rash has also been reported, usually within the first few weeks of treatment, and resolves with treatment discontinuation or, in some patients, with continued treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\tPeritonitis: Infectious and aseptic/sterile peritonitis have been reported; monitor for signs and symptoms of infection. Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, resulting in abdominal pain and/or peritonitis. If peritonitis occurs, treat with appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adept: Safety and efficacy have not been established for use in pregnancy, volumes left in peritoneal cavity &gt;1 L, hepatic or renal dysfunction, or with a breach in the vaginal epithelium. Effectiveness has not been established for long-term clinical outcomes following gynecologic surgery (eg, pregnancy, pain). Serious postoperative complications (dehiscence, cutaneous fistula formation) have been associated with laparotomy incision; anastomotic failure, ileus, and peritonitis have been reported following bowel resection or repair or appendectomy; use is contraindicated with these procedures. Postoperative leaking may occur through laparoscopic port site and may be associated with wound complications (eg, subcutaneous fluid collection, skin separation, and infection); meticulous closure of the fascia may help reduce complications. Use may be associated with vulvar swelling, most cases resolving within 1 week. Pulmonary edema, pulmonary effusion and arrhythmia have been reported (rarely); most commonly in elderly or debilitated patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extraneal: Over infusion may cause abdominal distention, feeling of fullness and/or shortness of breath; drain dialysis solution from the peritoneal cavity if overinfusion occurs. Monitor for lactic acidosis before and during treatment in patients at higher risk for developing lactic acidosis (eg, severe hypotension or sepsis associated with acute renal failure, inborn errors of metabolism, use of nucleoside/nucleotide reverse transcriptase inhibitors). Cases of encapsulating peritoneal sclerosis (some fatal) have been reported. Peritoneal dialysis may cause fluid, electrolyte, and nutrition imbalances; monitor closely to avoid hyper- or hypovolemia and potentially severe consequences including heart failure, volume depletion, and hypovolemic shock.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: <b>[US Boxed Warning]: Due to potential interference by maltose, careful attention must be given to glucose monitoring; only glucose monitors and test strips which employ the glucose-specific method should be used. Inaccurate methods (glucose dehydrogenase pyrroloquinolinequinone [GDH-PQQ], glucose-dye-oxidoreductase methods [GDO], and some glucose dehydrogenase flavin-adenine dinucleotide [GDH-FAD]-based methods) can result in falsely-elevated glucose readings and must not be used.</b> Inaccurate readings may mask recognition of true hypoglycemia, or may prompt the administration of insulin, potentially leading to life-threatening consequences. Falsely-elevated glucose levels may be measured up to 2 weeks following cessation of icodextrin therapy when GDH-PQQ, GDO, and GDH-FAD-based blood glucose monitors and test strips are used. Because GDH-PQQ, GDO, and GDH-FAD-based blood glucose monitors may be used in hospital settings, it is important that the health care providers of peritoneal dialysis patients carefully review the product information of the blood glucose testing system, including that of test strips, to determine if the system is appropriate for use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299507\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220946\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8769&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181598\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181609\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20620018\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if icodextrin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering icodextrin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181600\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum electrolytes, blood chemistry; fluid balance, weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extraneal: Monitor for lactic acidosis before and during treatment in patients at higher risk for developing lactic acidosis (eg, severe hypotension or sepsis associated with acute renal failure, inborn errors of metabolism, use of nucleoside/nucleotide reverse transcriptase inhibitors).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181591\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">When used for dialysis, icodextrin exerts osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration throughout the dwell while providing electrolytes and lactate for the maintenance of both the electrolyte and acid-base balance. When used for laparoscopic surgery, the colloidal osmotic action allows the fluid to be retained in the peritoneal cavity for 3 to 4 days, physically providing a temporary separation of peritoneal surfaces and minimizing adhesion formation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181606\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: 40% during 12-hour dwell (CAPD); slowly transferred into systemic circulation via peritoneal lymphatic drainage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily by alpha-amylase into maltose (DP2), maltotriose (DP3), maltotetraose (DP4), and higher molecular weight species </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 13 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Renal (amount proportional to residual renal function); diasylate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326128\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Extraneal Intraperitoneal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5% (2000 mL): $107.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038656\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Extraneal (AE, AT, ES, HR, KR, KW, LB, LT, LV, MT, PL, PT, QA, RO, SA, SI, SK, VN);</li>\n      <li>Extraneal Dialysis Solution (AR, AU, BE, CH, CZ, DK, EE, FI, FR, HN, IE, IL, IT, NL, NO, NZ, SE, SG, TH, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Extraneal (icodextrin peritoneal dialysis solution) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Extraneal (icodextrin peritoneal dialysis solution) [product monograph]. Mississauga, Ontario, Canada: Baxter Co.; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frampton JE and Plosker GL, &ldquo;Icodextrin: a review of its use in peritoneal dialysis,&rdquo; <i>Drugs</i>, 2003, 63(19):2079-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/icodextrin-drug-information/abstract-text/12962523/pubmed\" target=\"_blank\" id=\"12962523\">12962523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutton C, Minelli L, Garcia E, et al, &ldquo;Use of Icodextrin 4% Solution in the Reduction of Adhesion Formation After Gynaecological Surgery,&rdquo; <i>Gynecol Surg</i>, 2005, 2(4): 287-296.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8769 Version 88.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7869323\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181621\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49308227\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181636\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181622\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181623\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181602\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181590\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8104265\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181604\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181603\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F4432013\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181594\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181607\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181592\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299507\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220946\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F181598\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181609\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20620018\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181600\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181591\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181606\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28326128\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038656\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8769|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=icodextrin-patient-drug-information\" class=\"drug drug_patient\">Icodextrin: Patient drug information</a></li></ul></div></div>","javascript":null}